AzTrials
AzTrials

Bone Loss, AlveolarNCT06204588

Evaluation of Regenerative Potential in Horizontal Bone Loss Using VCMX Along With LASER Therapy

A study testing Test group 1: VCMX + Low level LASER therapy + Single flap approach and Test group 2: Low level LASER therapy + Single flap approach in people with Bone Loss, Alveolar, run by Postgraduate Institute of Dental Sciences Rohtak at 1 site in India.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Background- Periodontitis, an inflammatory disease of the periodontium, is one of the major causes of tooth mortality. Of all the bone destruction patterns that are present in periodontitis, horizontal bone loss is the most common. Read more about this study

Who is it for?
Ages 18 to 45 yearsHealthy volunteers can take part
Conditions the study is for
Bone Loss, Alveolar
What is being tested?
Test group 1: VCMX + Low level LASER therapy + Single flap approach and Test group 2: Low level LASER therapy + Single flap approach
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 siteIndia
Study dates
1 Apr 2024to Mar 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Periodontitis stage 2 and stage 3 patients will be enrolled according to criteria of 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions
  • Horizontal bone loss defects with depth ≥ 5 mm (initially analyzed by trans-gingival probing and intraoral periapical radiographs and will be confirmed further after flap elevation and CBCT)
  • PPD ≥ 5 mm
  • CAL ≥ 3 mm
  • Tooth mobility < grade 1
  • Experimental teeth and adjacent teeth would be required to be vital and free of caries or dental restorations

Who cannot join

  • Any systemic illness that could affect the periodontium or outcome of periodontal therapy
  • patients on medications such as corticosteroids or calcium channel blockers
  • long-term nonsteroidal anti-inflammatory drug therapy
  • pregnant or lactating women
  • current and past smoker
  • Periodontitis stage 4
  • teeth with one-wall defect, the presence of exostoses and ledges, grade II and grade III mobile teeth, defects extending to a root furcation area, unrestorable teeth, fractured/perforated roots, developing permanent teeth, endodontically treated teeth, and teeth with premature contact and dental prosthesis.

Trial locations and contacts

1 site in 1 country.

India1 site, 1 recruiting
  • Post Graduate Institute of Dental Sciences

    Rohtak, Haryana, 124001

    Shikha Tewari, MDS

    Recruiting

Other trials in India

About this study

Official title: Clinical and Radiographic Evaluation of Volume Stable Collagen Matrix (VCMX) in the Regenerative Outcome of Periodontal Horizontal Bone Loss When Used With Diode Laser Therapy in Humans: A Randomized Controlled Clinical Trial

Background- Periodontitis, an inflammatory disease of the periodontium, is one of the major causes of tooth mortality. Of all the bone destruction patterns that are present in periodontitis, horizontal bone loss is the most common. Therefore, treatment modalities that help in rebuilding horizontal defects are vital in total periodontal reconstruction.

Rationale- The supracrestal bone regeneration in cases of horizontal bone loss has remained a mirage with very little recorded success. Volume stable collagen matrix(VCMX), is a porous, cross-linked collagen matrix of porcine origin designed to facilitate cell and vascular ingrowth and soft-tissue volume augmentation, may be beneficial in maintaining the supracrestal space and may overcome the limitation of bone regeneration in horizontal defects. Evidence has shown that Low level laser therapy(LLLT) based on principal of biostimulation of osteoclastic cells, can have a positive effect on the regeneration of supracrestal bone in horizontal bone destruction. So, this study will be first of its kind using combination of VCMX with LLLT to assess regenerative outcome in treatment of horizontal bone destruction in patients with periodontitis.

Read more

Objectives: To assess clinical and radiographic regenerative outcome of periodontal tissues using LLLT and placing VCMX with single flap approach(SFA) in treatment of horizontal bone loss as compared to LLLT and SFA.

Method: A total of 60 patients will be randomly divided into three groups: Test Group 1: VCMX +LLLT +SFA, Test Group 2:LLLT+SFA, and Control group: SFA. Periodontal parameters will be evaluated at baseline, 3, 6, and 9 months. CBCT will be evaluated at baseline and 9 months.

Expected outcome: VCMX with Laser could achieve supracrestal bone regeneration in horizontal bone loss.

Read the detailed description

Periodontitis is a chronic inflammatory disease triggered by gram-negative anaerobic microbes and involves chronic inflammation that causes the destruction of the tooth-supporting apparatus and can lead to tooth loss.1 Periodontal disease is responsible for decreasing alveolar bone height along with morphologic changes of alveolar bone. Various pattern of bone loss was observed clinically horizontal and vertical pattern of bone loss are most commonly seen in periodontitis cases.2 Various factors that determine bone loss patterns are teeth alignments in arch root position within the alveolar socket and root proximity with the adjacent tooth surface.3 Kern et al in 1984 called this horizontal bone defect as zero wall defects. In this type of defect bone margin reduction occurs horizontally and its margin lies perpendicular to tooth surface. Horizontal pattern of bone loss is most commonly seen in human dentition4 but it receives very less attention in terms of treatment modalities. The prevalence of vertical bone loss was 7.8% with treatment choices of 96.8% while the horizontal bone loss prevalence rate was 92.2% and undergo 3.2% treatment options only.5 Due to no bone wall remaining for the support and stability of grafts and membranes, leads to a very low success rate of horizontal bone defects treatment modalities. To regenerate the lost part of the alveolar bone is always a challenge for both clinician and patient.

Several attempts have been done for the treatment of horizontal bone defects using bone grafts, membranes, or a combination of grafts and membranes. Recently recombinant human bone morphogenic protein (rhBMP) and enamel matrix proteins(EMPs) have been assessed for the management of horizontal defects. But their results were mixed and sometimes disappointing. The single flap approach (SFA) is a simplified minimally invasive surgical approach that enhances primary closure and minimizes tissue trauma. The principle behind using this approach is that elevation of the limited mucoperiosteal flap allows surgical access from either the buccal or palatal/lingual aspect only depending on the extension of the lesion, leaving the interdental supracrestal gingival tissue intact. Main advantages associated with this approach that flap repositioning and suturing to the undetached papilla, thereby preventing contamination by blood clots and reduction in post-surgical reduction. Due to the emergence of biologic approach and biomaterials there is improved concern toward of horizontal defects. Various factors determine the outcomes like patient-related factors, site-related and clinician related factors. Laser technology now a days becoming popular in various medical applications like photodynamic therapy. Low level laser therapy (LLLT) also called photo-biomodulation enhance wound healing based on the principle of biomodulatory capacity of laser on body cells leading to increased cell activity.12 It reduces excessive post-operative inflammation, edema and pain. LLLT can promote bone regeneration by enhancing proliferation and differentiation of human osteoblasts.14 According to Gavish et al 780nm diode laser shown to inhibit the gene expression of pro-inflammatory cytokines interleukin-1 beta(IL-1β) ,modulate matrix metalloproteinase (MMPs) activity15 and reduce monocyte chemotactiprotein-1 (MCP-1), IL-1α, IL-10 and IL-6 in lipopolysaccharide-stimulated macrophages.16 Numerous treatment approaches for restoring such defects have been investigated. Despite laudable record, autografts have been questioned for surgical invasiveness, donor site morbidity, limited quantity of donor material and increased operating time for harvesting procedures.17 Limitations of the use of osteoinductive grafts is variation in bone induction capacity sourced from different tissue banks.18,19 When used in intrabony defects, Enamel Matrix Derivative(EMD) may restrict the space provision potential of the preparation.20 Further, application of EMD is a technique sensitive procedures and contamination of the material jeopardizing the regenerative potential. The lack of rigidity and rapid degradation (biodegradability) make the use of PRF for periodontal regeneration difficult. Nanocomposites and nanostructured materials are thought to have a key function in hard tissue research, since natural bone tissue is a distinctive model of a nanocomposite. Collagen has been potentially used in periodontal tissue engineering. The integration of collagen as a structural protein, serving as an essential component of connective tissue into three-dimensional scaffolds implanted after periodontal injury, necrosis or inflammation has attracted much attention in tissue regeneration.

According to Ibara et al, scaffolds to be implanted are durable if composed of nanoparticles. The nanoparticles facilitate healing process in contact with the tissues intended for the reformation. Recently, Thoma et al developed and tested collagen-based matrices as potential devices for soft tissue volume augmentation. Volume stable collagen matrix (VCMX) is able to overcome the volume stability limitation of most commercially available grafts.21 It is one of the most biocompatible, novel material to be used in this study. While mechanical stability is achieved by chemical crosslinking, mechanical testing demonstrated preserved elasticity of the material over 14 days.22 It has shown quite impressive results in resolving the intrabony defects in animal studies with an average of 58.56% of new bone formation .23 Imber J-C et al23, preclinically evaluated the effect of a volume-stable collagen matrix on periodontal regeneration in two-wall intrabony defects. This study provided histologic evidence for the potential of this novel VCMX to facilitate periodontal regeneration. Asparuhova, M.B et al24 investigated the influence of a novel volume-stable collagen matrix (VCMX) on early wound healing events including cellular migration and adhesion, protein adsorption and release, and the dynamics of the hemostatic system. Their study concluded that their data strongly support the effect of the novel VCMX on fibrin clot stabilization and coagulation/fibrinolysis equilibrium, thus facilitating progression to the next stages of the soft tissue healing process.

Therefore, the present study was planned to evaluate the supracrestal regenerative potential of volume stable collagen matrix (VCMX) along with single flap approach(SFA) when used with diode laser in the treatment of horizontal bone defect of stage 2 and 3 patients in comparison to OFD with diode laser and OFD alone.

Methodology:

  • Study design and settings: The study design is "Randomized controlled clinical trial" and will be conducting in Department of Periodontology, Post graduate Institute of Dental Sciences, Rohtak, Haryana.
  • Study population:

Systemically healthy patients with periodontitis stage 2 and stage 3 having horizontal bone loss will be enrolled in the present study.

I Study conduct: Patients will be enrolled according to inclusion and exclusion criteria from the outpatient department of periodontics, Post Graduate Institute of Dental Sciences, Rohtak, Haryana. Informed and written consent will be taken from each patient in his or her language.

Randomization of patients would be done by generating the allocation sequence using computer-generated table by another investigator. Patients will be randomly allocated into:

  • Control group: using single flap approach only
  • Test group 1: using collagen matrix and laser therapy in horizontal bone loss defects by single flap approach (SFA+VCMX+LLLT).
  • Test group 2: Single flap approach along with diode laser (SFA+LLLT). A balanced, permuted block approach (in blocks of four and six patients) will be used to prepare the randomization tables. After the debridement of the bone defect, the eligibility of the bone defect would be confirmed. Allocation concealment will be performed by opaque sealed envelopes that would be opened after debridement of horizontal bone loss defects, and the surgeon will be informed of the allocated treatment. Although the surgeon won't be blinded to the treatments, the examiners recording clinical and radiographic parameters would be blind to the treatment groups. Minimum One horizontal bone defect per patient will be included in the study.

Periodontal parameters:

Parameters recorded for experimental and adjacent teeth will include: PIaque index (PI) and Gingival Index (GI), assessed at six surfaces (mesiobuccal, midbuccal, distobuccal, midlingual/midpalatal, mesiolingual, distolingual); bleeding on probing (BOP, %), PPD, CAL, and gingival recession (REC), examined at six surfaces (mesiobuccal, midbuccal, disto-buccal, mesiolingual/mesiopalatal, midlingual/midpalatal, distolingual/distopalatal).

Radiographic Parameters that will be assessed using CBCT will include alveolar crest changes (ACC).Outcome measures will be revaluated at 3, 6, \& 9 months interval

Intervention:

Presurgical patient preparation:

Patients diagnosed with periodontitis who will meet the inclusion criteria will be screened for periodontal examination. Based on this examination, target sites will be identified. Each patient will receive the initial phase of the therapy, which will include oral hygiene instructions, supragingival and subgingival debridement using ultrasonic (Piezon®, EMS Dental, Nyon, Switzerland) and hand instrumentations (Gracey Curettes,Hu- Friedy®, Chicago, IL, USA), and relieving of occlusal trauma.

Surgical procedure:

Surgical sites will be anaesthetized using local anaesthesia. Simplified Papilla Preservation flap technique will be exercised using single flap approach. Crevicular incisions will be made on buccal/lingual/palatal sites to raise a full-thickness mucoperiosteal flap. Precaution would be taken to preserve the maximum interdental gingival tissue at the time of crevicular incision, and no bone recontouring would be performed. Thorough debridement of the surgical site would be performed For the test group1, VCMX would be placed according to the dimensions of the horizontal bone loss defect along with the use of diode laser (LLLT) on the inner epithelium of flap. For the test group 2, SFA will be done along with the use of diode laser (LLLT). For control group, SFA will be done. And after this, flap would be approximated and sutured at the original position with a monofilament suture material using interrupted sutures.

Instructions for maintenance of proper oral hygiene will be reinforced. Study participants will be scheduled for a follow-up visit weekly to1-month postsurgery and subsequently at 3-, 6-, and 9-month intervals.

All statistical tests will use two-sided P values, and statistical software will be used in the analysis of the study data. Differences associated with P values 0.05 will be considered statistically significant.

Being tested
control group: SFA only, Test group 1: VCMX + Low level LASER therapy + Single flap approach, Test group 2: Low level LASER therapy + Single flap approach
Medical subject headings
Alveolar Bone Loss

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • control group: SFA onlyProcedure or surgery

    Single flap approach

  • Test group 1: VCMX + Low level LASER therapy + Single flap approachProcedure or surgery

    using collagen matrix and laser therapy in horizontal bone loss defects by single flap approach (SFA+VCMX+LLLT).

  • Test group 2: Low level LASER therapy + Single flap approachProcedure or surgery

    Laser therapy in horizontal bone loss defects by single flap approach (SFA+LLLT).

Study groups in NCT06204588
Study groupRoleWhat they receive
Test group-1Experimentalusing collagen matrix and laser therapy in horizontal bone loss defects by single flap approach (SFA+VCMX+LLLT).
Receives: Procedure: Test group 1: VCMX + Low level LASER therapy + Single flap approach
Test group-2ExperimentalSingle flap approach along with diode laser (SFA+LLLT).
Receives: Procedure: Test group 2: Low level LASER therapy + Single flap approach
Control groupExperimentalusing single flap approach only
Receives: Procedure: control group: SFA only

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Clinical attachment level

    Periodontal probe will be used to measure clinical attachment level

    Measured: 24 months

  2. alveolar bone level

    transgingival probing using periodontal probe and by radiographically using CBCT

    Measured: 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Jan 2024
  2. Study start1 Apr 2024
  3. Primary completionMar 2025 (estimated)
  4. Study completionMar 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Investigator
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06204588
Sponsor's protocol ID
Shikha IMRG Perio
Status last verified
May 2024
First submitted
14 Dec 2023
Last updated
17 May 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Test group 1: VCMX + Low level LASER therapy + Single flap approach and Test group 2: Low level LASER therapy + Single flap approach in people with Bone Loss, Alveolar, run by Postgraduate Institute of Dental Sciences Rohtak at 1 site in India.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 17 May 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Tewari Sanjay (01262 ext. 213876, principalpgids@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Clinical attachment level (time frame: 24 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 May 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in